Skip to content

About CLTI
Contact
International

Technology
- Products
- Instructions for Use
Healthcare Professionals
Clinical Evidence
U.S. Clinical Trial
Reimbursement Resources
Patients
Company
- Clinical Advisors
- News
- Media
- Articles
- Careers

Jun 6 2017

LimFlow Expands Senior Management Team and Opens Silicon Valley Office

View the article.

LimFlow Receives FDA Approval for U.S. Feasibility Study of Minimally-Invasive Technology Designed to Restore Perfusion in “No Option” Critical Limb Ischemia Patients Midterm Outcomes From a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option Critical Limb Ischemia

Related Posts

FDA APPROVES LIMFLOW SYSTEM IN PATIENTS WITH CHRONIC LIMB-THREATENING ISCHEMIA AND NO SUITABLE ENDOVASCULAR OR SURGICAL REVASCULARIZATION OPTIONS

LANDMARK NEW ENGLAND JOURNAL OF MEDICINE PUBLICATION REPORTS POSITIVE RESULTS FROM PROMISE II PIVOTAL TRIAL SHOWING THAT LIMFLOW SYSTEM SAVES MOST PATIENTS WITH END-STAGE PERIPHERAL ARTERY DISEASE FROM MAJOR AMPUTATION

LIMFLOW APPOINTS MIKE MATHIAS AS VICE PRESIDENT, COMMERCIAL OPERATIONS

Recent Posts

FDA APPROVES LIMFLOW SYSTEM IN PATIENTS WITH CHRONIC LIMB-THREATENING ISCHEMIA AND NO SUITABLE ENDOVASCULAR OR SURGICAL REVASCULARIZATION OPTIONS
LANDMARK NEW ENGLAND JOURNAL OF MEDICINE PUBLICATION REPORTS POSITIVE RESULTS FROM PROMISE II PIVOTAL TRIAL SHOWING THAT LIMFLOW SYSTEM SAVES MOST PATIENTS WITH END-STAGE PERIPHERAL ARTERY DISEASE FROM MAJOR AMPUTATION
LIMFLOW APPOINTS MIKE MATHIAS AS VICE PRESIDENT, COMMERCIAL OPERATIONS
LIMFLOW APPOINTS JENNY GAFFNEY AS VICE PRESIDENT, HEALTH ECONOMICS AND REIMBURSEMENT
LIMFLOW RAISES $40 MILLION (€36 MILLION) IN SERIES D FINANCING

LimFlow_Logo White R

LimFlow Story:

Privacy:

Ethics Hotline
Compliance

Contact:

info@limflow.com
+1 (877) 923-4747